Linezolid Kabi Dosage/Direction for Use

General Dosage and Administration: The recommended dosage for Linezolid Kabi for the treatment of infections is described in Table 11. (See Table 11.)

Click on icon to see table/diagram/image

Intravenous Administration: Linezolid Kabi is supplied in single use, ready-to-use flexible plastic containers. Parenteral drug products should be inspected visually for particulate matter prior to administration. Keep the bottle in the outer carton until ready to use. Do not store above 30°C. Protect from freezing. Linezolid Kabi may exhibit a yellow color that can intensify over time without adversely affecting potency.
Linezolid Kabi should be administered by intravenous infusion over a period of 30 to 120 minutes. Do not use this intravenous flexible plastic container in series connections. Additives should not be introduced into this solution. If Linezolid Kabi is to be given concomitantly with another drug, each drug should be given separately in accordance with the recommended dosage and route of administration for each product. Discard unused portion.
If the same intravenous line is used for sequential infusion of several drugs, the line should be flushed before and after infusion of Linezolid Kabi with an infusion solution compatible with Linezolid Kabi and with any other drug(s) administered via this common line.
Compatibilities: Compatible intravenous solutions include Sodium Chloride 0.9% w/v, Dextrose 5%, and Ringer's Lactate.
Incompatibilities: Physical incompatibilities resulted when Linezolid Kabi was combined with the following drugs during simulated Y-site administration: amphotericin B, chlorpromazine HCl, diazepam, pentamidine isothionate, erythromycin lactobionate, phenytoin sodium, and trimethoprim-sulfamethoxazole. Additionally, chemical incompatibility resulted when Linezolid Kabi was combined with ceftriaxone sodium.